Protara Therapeutics (TARA) Accounts Payables (2013 - 2026)

Protara Therapeutics (TARA) has reported Accounts Payables for 14 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables rose 74.5% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 74.5% YoY), while the FY2025 annual figure was $3.5 million, down 21.7% from the prior year.
• Accounts Payables improved to $4.0 million in Q1 2026 per TARA's latest filing, from $3.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $5.3 million in Q2 2025 and bottomed at $392000.0 in Q2 2022.
• Historically, Accounts Payables has averaged $2.5 million across 5 years, with a median of $2.3 million in 2025.
• Annual changes were most pronounced in 2023 — Accounts Payables jumped 654.34% — and 2024, when it sank 76.18%.
• Protara Therapeutics' Accounts Payables stood at $1.6 million in 2022, then surged by 53.47% to $2.4 million in 2023, then surged by 81.96% to $4.4 million in 2024, then retreated by 21.7% to $3.5 million in 2025, then grew by 16.23% to $4.0 million in 2026.
• Business Quant data shows TARA's Accounts Payables at $4.0 million in Q1 2026, $3.5 million in Q4 2025, and $4.5 million in Q3 2025.